Skip to content
OpenCapital
Get started

AbbVie ABBV Imbruvica — Net revenues

Other product segments

Skyrizi
$4.48B+30.9%
Rinvoq
$2.12B+23.3%
All other
$1.03B-18.2%
Botox Therapeutic
$1.01B+16.5%
Vraylar
$905M+18.3%
Venclexta
$770M+15.8%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Vyalev
$201M+219%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

Johnson & Johnson logo
JNJIMBRUVICA — Sales to customers (Note 9)
$599M-18.5%
Johnson & Johnson logo
JNJIMBRUVICA — Percent Change (as a percent)
-18.6%-27.3pp
Pfizer logo
PFEIbrance — Revenues:
$1.01B+3.2%
ANI Pharmaceuticals logo
ANIPILUVIEN and YUTIQ — Net Revenues
$19.26M+19.5%
Amneal Pharmaceuticals, Inc. logo
AMRXBiosimilar — Net revenue
$22.3M-21.9%
Organon logo
OGNInt’l — Revenue
$1.1B+0.1%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's imbruvica — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's imbruvica — net revenues?
AbbVie (ABBV) reported imbruvica — net revenues of $556M in Q1 2026.
How has AbbVie's imbruvica — net revenues changed year-over-year?
AbbVie's imbruvica — net revenues decreased by 24.7% year-over-year, from $738M to $556M.
What is the long-term trend for AbbVie's imbruvica — net revenues?
Over 4 years (2021 to 2025), AbbVie's imbruvica — net revenues has grown at a -14.7% compound annual growth rate (CAGR), from $5.41B to $2.87B.
What does imbruvica — net revenues mean?
This metric represents the total net sales generated by the Imbruvica product line after accounting for returns, rebates, and discounts. It is a primary measure of the product's commercial success and market penetration within its therapeutic area. Tracking this allows investors to evaluate the product's lifecycle stage and its contribution to the company's overall top-line growth.